RedHill Biopharma Ltd. reports 62% mortality reduction in moderately severe COVID-19 patients treated with oral opaganib in new analysis of data from global Phase 2/3 study
"These new findings support the potential for opaganib's use in hospitalized, moderately severe COVID-19 patients - a key group of patients that are at...